mRNA and multi-epitope-based vaccines (MVC) against Mpox were designed using proteomics and structural vaccinology methods in this study. First, researchers isolated 10 proteins from the Mpox proteome that may be used as vaccine targets. Epitopes of these proteins were then mapped using structural ...
delivery, numerous non-viral delivery systems have been tested and applied to overcome the natural susceptibility of mRNA to enzymatic degradation [220,225,242]. The successful development of mRNA-based COVID-19 vaccines has opened up exciting new opportunities for novel mRNA-based drugs and vaccine...
mRNA vaccines have emerged as a revolutionary tool to generate rapid and precise immune responses against infectious diseases and cancers. Compared with conventional vaccines such as inactivated viruses, viral vectors, protein subunits or DNA-based vaccines, mRNA vaccines stand out owing to multiple adva...
delivery, numerous non-viral delivery systems have been tested and applied to overcome the natural susceptibility of mRNA to enzymatic degradation [220,225,242]. The successful development of mRNA-based COVID-19 vaccines has opened up exciting new opportunities for novel mRNA-based drugs and vaccine...
Here, we performed a cross-sectional evaluation of immune response to three types of vaccines in patients with NS to further explore the presence of a clinically relevant B- and/or T-cell immunodeficiency. Immune responses after vaccination with a polysaccharide Streptococcus pneumoniae vaccine (PPV23...
Although mRNA vaccines are known as potent activators of antigen-specific immune responses against infectious diseases, limited understanding of how they drive the functional commitment of CD8+ T cells in tumor microenvironment (TME) and secondary lympho
“We don’t know when the next Disease X will emerge, but we know it is coming,” CEPI CEO Richard Hatchett said. “Developing technologies in advance using mRNA allows us to avoid delays in creating new vaccines when a viral threat appears.” ...
-based Flu Vaccines Pfizer, BioNTech to Develop mRNA-based Flu VaccinesPfizer, BioNTech to Develop mRNA-based Flu Vaccines
“mRNA-based vaccines have demonstrated their ability to induce robust antibody and T-cell responses, and we look forward to starting Phase 3 clinical development. Today’s results are an important achievement towards our ambition of providing a broad portfolio of respiratory combination va...
Recently, mRNA-based vaccines have become a promising approach because of their opportunity for rapid development, comparative low dose, logical better safety profile in terms of no potential risk of infection or insertional mutagenesis, and low capital expenditure (CAPEX) [4]. Several other leading...